Clinical Trial Update: KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing KRT-232 to ruxolitinib in phlebotomy-dependent polycythemia vera is underway but status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• KRT-232
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Polycythemia Vera | Phase 2 | Status: UNKNOWN